🧵 1/10 The arc: POLAR - MDF – TIE Pancreatic cancer is profoundly resistant to immune checkpoint inhibitors. Yet, POLAR (pembrolizumab plus olaparib) trial showed that a subset of patients, especially with HRD (gBRCA2/1m or gPALB2m) tumors, can achieve remarkably durable control. That led us to two questions: #1 👆🏼what makes these tumors immunogenic? #2 ✌️what makes that immunity actually work? 👑 #2. POLAR TIE @biorxivpreprint biorxiv.org/content/10.64898… #1. MDF biorxiv.org/content/10.64898… #0. POLAR @NatureMedicine nature.com/articles/s41591-0… #cancer #immunotherapy #PancreaticCancer #ICI #BRCA #HRD #3episodes @MSKCancerCenter @MSK_DeptOfMed @CpcrMsk @ldiaz1971 @debschrag @PanCAN @oncodaily @OncoDailyGI @OncoAlert @OncBrothers @brunolarvol – at Manhattan, NY

Excited to speak at the 2026 International Symposium of Gastrointestinal Oncology (ISGIO), taking place October 2-3 in Fort Lauderdale, FL. Chaired by @EileenMOReilly @GIcancerDoc I'd love to see you there. Use code PARK for free registration: gotoper.com/isgiofof26 Yes, Central PARK @CentralParkWMD So many exciting clinical and scientific advances are changing how we treat GI cancers! 🔬💫 This multidisciplinary conference brings together leading experts to discuss new advances in GI cancer research and care. It's a great opportunity for oncologists, surgeons, nurses, and other GI cancer health care professionals to connect and dive into the latest treatment data and clinical strategies. #RAS #KRAS #GIOncology #GICancer #PrecisionOncology #CancerResearch #ClinicalTrials #pancsm – at Manhattan, NY

Thank you @wolfblitzer and @CNN for highlighting this milestone for #PancreaticCancer 💜 For more than four years I’ve had the privilege of helping develop daraxonrasib clinically and leading translational research while caring for patients with previously treated advanced disease. Some have had exceptional responses lasting years. Children’s weddings. Grandchildren’s graduations. Long-planned travels. Seeing these moments become possible has been a true joy in my clinic. That is what more time means. Now I lead MSK’s participation in RASolute-303 to test daraxonrasib as initial treatment for metastatic disease. Across the field we are also developing next-generation RAS inhibitors and degraders and testing novel combinations and treatment in earlier-stage disease. Our goal is to make this benefit deeper and longer-lasting for our patients. Grateful to fellow investigators including @EileenMOReilly and all the international investigators, our clinical and research teams and above all our courageous patients and families. This is why we do this work. And this is just the beginning. @CpcrMsk @MSK_DeptOfMed @RevMedicines @PanCAN @OncBrothers @OncoAlert @oncodaily @OncoDailyGI @lustgartenfdn – at Manhattan, NY

Now FDA finally delivered!! Please welcome 🎂 the new birth of 💫 “RASONque” Congrats 🎉🎊 to every investigator, nursing teams, research teams and courageous patients! #pancreaticcancer #PDAC @MSKCancerCenter @MSK_DeptOfMed @CpcrMsk @EileenMOReilly @MichaelMayMD @MarcHilmi @FiyinfoluB @schoenfeld_j @AnupriyaSingha9 fda.gov/news-events/press-an…